Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently
healthy men. N Engl J Med.1997;336:973-979.
Ernst E, Hammerschmidt DE, Bagge U. Leukocytes and the risk of ischemic disease. JAMA.1987;257:2318-2324.
Packard CJ, O'Reilly DS, Caslake MJ.
et al. for the West of Scotland Coronary Prevention Group. Lipoprotein-associated phospholipase A2 as an independent predictor
of coronary heart disease. N Engl J Med.2000;343:1148-1155.
Kullo IJ, Gau GT, Tajik AJ. Novel risk factors for atherosclerosis. Mayo Clin Proc.2000;75:369-380.
Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin or leukocyte
count with coronary artery disease: meta-analyses of prospective studies. JAMA.1998;279:1477-1482.
Nauseef WM. Myeloperoxidase deficiency—phagocytic defects, I: abnormalities
outside of the respiratory burst. Hematol Oncol Clin North Am.1988;2:135-158.
Malech HL, Nauseef WM. Primary inherited defects in neutrophil function: etiology and treatment. Semin Hematol.1997;34:279-290.
Heinecke JW. Mass spectrometric quantification of amino acid oxidation products
in proteins: insights into pathways that promote LDL oxidation in the human
artery wall. FASEB J.1999;13:1113-1120.
Podrez EA, Abu-Soud HM, Hazen SL. Myeloperoxidase-generated oxidants and atherosclerosis. Free Radic Biol Med.2000;28:1717-1725.
Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed
in human atherosclerotic lesions. J Clin Invest.1994;94:437-444.
Hazen SL, Heinecke JW. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation,
is markedly elevated in low-density lipoprotein isolated from human atherosclerotic
intima. J Clin Invest.1997;99:2075-2081.
Hazen SL, Gaut JP, Crowley JR, Hsu FF, Heinecke JW. Elevated levels of protein-bound p-hydroxyphenylacetaldehyde, an amino
acid-derived aldehyde generated by myeloperoxidase, are present in human fatty
streaks, intermediate lesions and advanced atherosclerotic lesions. Biochem J.2000;352:693-699.
Heller JI, Crowley JR, Hazen SL.
et al. p-Hydroxyphenylacetaldehyde, an aldehyde generated by myeloperoxidase,
modifies phospholipid amino groups of low density lipoprotein in human atherosclerotic
intima. J Biol Chem.2000;275:9957-9962.
Podrez EA, Schmitt D, Hoff HF, Hazen SL. Myeloperoxidase-generated reactive nitrogen species convert LDL into
an atherogenic form in vitro. J Clin Invest.1999;103:1547-1560.
Podrez EA, Febbraio M, Sheibani N.
et al. Macrophage scavenger receptor CD36 is the major receptor for LDL modified
by monocyte-generated reactive nitrogen species. J Clin Invest.2000;105:1095-1108.
Abu-Soud HM, Hazen SL. Nitric oxide is a physiological substrate for mammalian peroxidases. J Biol Chem.2000;275:37524-37532.
Hazen SL, Hsu FF, Heinecke JW. p-Hydroxyphenylacetaldehyde is the major product of L-tyrosine oxidation
by activated human phagocytes: a chloride-dependent mechanism for the conversion
of free amino acids into reactive aldehydes by myeloperoxidase. J Biol Chem.1996;271:1861-1867.
Klebanoff SJ, Waltersdorph AM, Rosen H. Antimicrobial activity of myeloperoxidase. Methods Enzymol.1984;105:399-403.
Capeillere-Blandin C. Oxidation of guaiacol by myeloperoxidase: a two-electron-oxidized guaiacoltransient
species as a mediator of NADPH oxidation. Biochem J.1998;336:395-404.
Markwell MA, Haas SM, Bieber LL, Tolbert NE. A modification of the Lowry procedure to simplify protein determination
in membrane and lipoprotein samples. Anal Biochem.1978;87:206-210.
Taylor AJ, Burke AP, O'Malley PG.
et al. A comparison of the Framingham risk index, coronary artery calcification,
and culprit plaque morphology in sudden cardiac death. Circulation.2000;101:1243-1248.
Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating.
factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol.2001;158:879-891.
Hazell LJ, Stocker R. Oxidation of low-density lipoprotein with hypochlorite causes transformation
of the lipoprotein into a high-uptake form for macrophages. Biochem J.1993;290:165-172.
Malle E, Hazell L, Stocker R, Sattler W, Esterbauer H, Waeg G. Immunologic detection and measurement of hypochlorite-modified LDL
with specific monoclonal antibodies. Arterioscler Thromb Vasc Biol.1995;15:982-989.
Savenkova ML, Mueller DM, Heinecke JW. Tyrosyl radical generated by myeloperoxidase is a physiological catalyst
for the initiation of lipid peroxidation in low density lipoprotein. J Biol Chem.1994;269:20394-20400.
Schmitt D, Shen Z, Zhang R.
et al. Leukocytes utilize myeloperoxidase-generated nitrating intermediates
as physiological catalysts for the generation of biologically active oxidized
lipids and sterols in serum. Biochemistry.1999;38:16904-16915.
Eiserich JP, Hristova M, Cross CE, Jones AD, Freeman BA, Halliwell B. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase
in neutrophils. Nature.1998;391:393-397.
Hazen SL, Zhang R, Shen Z.
et al. Formation of nitric oxide-derived oxidants by myeloperoxidase in monocytes:
pathways for monocyte-mediated protein nitration and lipid peroxidation in
vivo. Circ Res.1999;85:950-958.
Heinecke JW, Li W, Francis GA, Goldstein JA. Tyrosyl radical generated by myeloperoxidase catalyzes the oxidative
cross-linking of proteins. J Clin Invest.1993;91:2866-2872.
Beckman JS, Ye YZ, Anderson PG.
et al. Extensive nitration of protein tyrosines in human atherosclerosis detected
by immunohistochemistry. Biol Chem Hoppe-Seyler.1994;375:81-88.
Leeuwenburg C, Rasmussen JE, Hsu FF.
et al. Mass spectrometric quantification of markers for protein oxidation
bytyrosyl radical, copper, and hydroxyl radical in low density lipoprotein
isolated from human atherosclerotic plaque. J Biol Chem.1997;272:3520-3526.
Leeuwenburg C, Hardy MM, Hazen SL.
et al. Reactive nitrogen intermediates promote low density lipoprotein oxidation
in human atherosclerotic intima. J Biol Chem.1997;272:1433-1436.
Chisolm GM, Steinberg D. The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med.2000;28:1815-1826.
Carr AC, Myzak MC, Stocker R, McCall MR, Frei B. Myeloperoxidase binds to low density lipoprotein: potential implications
for atherosclerosis. FEBS Lett.2000;487:176-180.
Yang CY, Gu ZW, Yang M.
et al. Selective modification of apoB-100 in the oxidation of low density
lipoproteins by myeloperoxidase in vitro. J Lipid Res.1999;40:686-698.
Febbraio M, Podrez EA, Smith JD.
et al. Targeted disruption of the class B scavenger receptor CD36 protects
against atherosclerotic lesion development in mice. J Clin Invest.2000;105:1049-1056.
Biasucci LM, D'Onofrio G, Liuzzo G.
et al. Intracellular neutrophil myeloperoxidase is reduced in unstable angina
and acute myocardial infarction, but its reduction is not related to ischemia. J Am Coll Cardiol.1996;27:611-616.
Harrison JE, Schultz J. Studies on the chlorinating activity of myeloperoxidase. J Biol Chem.1976;251:1371-1374.
Peppin GJ, Weiss SJ. Activation of the endogenous metalloproteinase, gelatinase, by triggered
human neutrophils. Proc Natl Acad Sci U S A.1986;83:4322-4326.
Shabani F, McNeil J, Tippett L. The oxidative inactivation of tissue inhibitor of metalloproteinase-1
(TIMP-1) by hypochlorous acid (HOCI) is suppressed by anti-rheumatic drugs. Free Radic Res.1998;28:115-123.
Springman EB, Angleton EL, Birkedal-Hansen H, Van Wart HE. Multiple modes of activation of latent human fibroblast collagenase:
evidence for the role of a Cys73 active-site zinc complex in latency and a
"cysteine switch" mechanism for activation. Proc Natl Acad Sci U S A.1990;87:364-368.
Abu-Soud HM, Hazen SL. Nitric oxide modulates the catalytic activity of myeloperoxidase. J Biol Chem.2000;275:5425-5430.
Abu-Soud HM, Khassawneh MY, Sohn JT, Murray P, Haxhiu MA, Hazen SL. Peroxidases inhibit nitric oxide (NO)-dependent bronchodilation: development
of a model describing NO-peroxidase interactions. Biochemistry.2001;40:11866-11875.
Abu-Soud HM, Hazen SL. Nitric oxide is a physiological substrate of plant and mammalian peroxidases. Nitric Oxide.2000;4:179.
Kutter D, Devaquet P, Vanderstocken G, Paulus JM, Marchal V, Gothot A. Consequences of total and subtotal myeloperoxidase deficiency: risk
or benefit? Acta Haematol.2000;104:10-15.
Nikpoor B, Turecki G, Fournier C, Theroux P, Rouleau GA. A functional myeloperoxidase polymorphic variant is associated with
coronary artery disease in French-Canadians. Am Heart J.2001;142:336-339.
Brennan ML, Anderson MM, Shih DM.
et al. Increased atherosclerosis in myeloperoxidase-deficient mice. J Clin Invest.2001;107:419-430.
Owen CA, Campbell MA, Boukedes SS, Stockley RA, Campbell EJ. A discrete subpopulation of human monocytes expresses a neutrophil-like
proinflammatory (P) phenotype. Am J Physiol.1994;267:L775-L785.
Akiyama Y, Miller PJ, Thurman GB.
et al. Characterization of human blood monocyte subset with low peroxidase
activity. J Clin Invest.1983;72:1093-1095.
Chisolm III GM, Hazen SL, Fox PL, Cathcart MK. The oxidation of lipoproteins by monocytes-macrophages: biochemical
and biological mechanisms. J Biol Chem.1999;274:25959-25962.